30.74%| YTD | 1Yr | 3Yr | 5Yr | 10Yr | |
| Fund | 30.74 | 50.26 | 0.70 | 8.65 | 8.26 |
| Classification | 30.78 | 61.45 | -4.23 | 4.90 | 1.71 |
| Index (S&P 500) | 23.50 | 48.80 | -5.90 | 0.70 | -0.90 |
| % Rank in Class (1-best,100=worst) | 58 | 78 | 4 | 5 | 6 |
| Investment Objective: | International |
|---|---|
| Net Assets ($Mil) | 5,364.30 |
| Inception Date: | 5/28/98 |
| Manager Name, Tenure | Fries/Trevisani/Wang, 1998 / 2006 / 2006 |
| Expense Ratio: | 1.28% |
|
Sales Charge:
Load Type:
|
Front-End Load 4.50% 0.00% |
| Company Name | Symbol | % Net Assets |
|---|---|---|
| Teva Pharmaceutical Industries Ltd | TEVA | 3.36 |
| Novo Nordisk A/s | NONOF | 2.48 |
| Komatsu Ltd | KMTUF | 2.40 |
| Lvmh Moet Hennessy Louis Vuitton Sa | LVMHF | 2.39 |
| Ntionl Bk Greece | NA | 2.39 |
| Industrial And Commercial Bank Of China Ltd | IDCBF | 2.37 |
| Standard Chartered Plc | SCBFF | 2.36 |
| Sap Ag | SAPGF | 2.33 |
| Hong Kong Exchanges And Clearing Ltd | HKXCF | 2.33 |
| Bnp Paribas Sa | BNPQF | 2.23 |
| % of Total Holdings | 24.64 | |